Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LML134 First-in-human Study
NCT02334449Phase 1Completed
- Sponsor
- Novartis
- Start
- Feb 2015
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LML134 in shift work sleep disorder (SWSD) and Hypersomnia (HS) (2 arms), sponsored by Novartis. Primary endpoints: Adverse events assessments, Cardiovascular safety assessments and 2 more. Started Feb 2015; status: completed.
02
Drugs
LML134
03
Conditions
shift work sleep disorder (SWSD)Hypersomnia (HS)
Beyond the preview
Go deeper on NCT02334449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02334449.